{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:50:00Z","timestamp":1776084600154,"version":"3.50.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Jiangxi Provincial Graduate Innovation Special Fund Project","award":["(Grant No. YC2025-S790)"],"award-info":[{"award-number":["(Grant No. YC2025-S790)"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(Grant No. 32360216)"],"award-info":[{"award-number":["(Grant No. 32360216)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Jiangxi Province","award":["(Grant No. 20252BAC200457)"],"award-info":[{"award-number":["(Grant No. 20252BAC200457)"]}]},{"name":"the Joint Program for Science and Technology & Healthcare of Ganzhou City","award":["(Grant No. 2025YLCE0104)"],"award-info":[{"award-number":["(Grant No. 2025YLCE0104)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04955-0","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:47:23Z","timestamp":1772707643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Shuzhou","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengwei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lincai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"9674","key":"4955_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361.","journal-title":"Lancet"},{"issue":"6","key":"4955_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4955_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296\u2013307.","journal-title":"Blood"},{"issue":"17","key":"4955_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"7","key":"4955_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la C\u00e1mara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56(7):1651\u201364.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"4955_CR6","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214\u20139.","journal-title":"Blood"},{"issue":"12","key":"4955_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"22","key":"4955_CR8","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"22","key":"4955_CR9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091\u2013101.","journal-title":"N Engl J Med"},{"issue":"8","key":"4955_CR10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18(8):1150\u201363.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"4955_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","volume":"124","author":"SG Holtan","year":"2014","unstructured":"Holtan SG, Marcelo P, Weisdorf DJ. Acute graft-versus-host disease: A bench-to-bedside update. Blood. 2014;124(3):363\u201373.","journal-title":"Blood"},{"issue":"20","key":"4955_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","volume":"135","author":"M Jagasia","year":"2020","unstructured":"Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739\u201349.","journal-title":"Blood"},{"issue":"1","key":"4955_CR13","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.","journal-title":"Cell Death Dis"},{"issue":"10","key":"4955_CR14","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838\u201343.","journal-title":"Blood"},{"issue":"4","key":"4955_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"5411","key":"4955_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143\u20137.","journal-title":"Science"},{"issue":"5","key":"4955_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1634\/stemcells.22-5-675","volume":"22","author":"MA Baxter","year":"2004","unstructured":"Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22(5):675\u201382.","journal-title":"Stem Cells"},{"issue":"3","key":"4955_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","volume":"20","author":"M Introna","year":"2014","unstructured":"Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transpl. 2014;20(3):375\u201381.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4955_CR19","doi-asserted-by":"crossref","unstructured":"Morata-Tarifa C, Mac\u00edas-S\u00e1nchez MDM, Guti\u00e9rrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease - A meta-analysis. Stem Cell Res Therapy. 2020;11(1):64.","DOI":"10.1186\/s13287-020-01592-z"},{"issue":"1","key":"4955_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.20517\/evcna.2025.02","volume":"6","author":"B Giebel","year":"2025","unstructured":"Giebel B. A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy. Extracell Vesicles Circ Nucl Acids. 2025;6(1):183\u201390.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"6","key":"4955_CR21","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"issue":"10","key":"4955_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/aje\/kwg074","volume":"157","author":"LA McNutt","year":"2003","unstructured":"McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940\u20133.","journal-title":"Am J Epidemiol"},{"key":"4955_CR23","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis: Wiley; 2021.","DOI":"10.1002\/9781119558378"},{"issue":"9","key":"4955_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/sim.2010","volume":"24","author":"A Thakkinstian","year":"2005","unstructured":"Thakkinstian A, McElduff P, D\u2019Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291\u2013306.","journal-title":"Stat Med"},{"issue":"29","key":"4955_CR25","first-page":"4679","volume":"21","author":"JF Xiang","year":"2017","unstructured":"Xiang JF. Effect of human umbilical cord mesenchymal stem cells on immune reconstruction of acute lymphoblastic leukemia children undergoing allogeneic hematopoietic stem cell transplantation. Chin J tissue Eng Res. 2017;21(29):4679\u201384.","journal-title":"Chin J tissue Eng Res"},{"issue":"24","key":"4955_CR26","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, Zhang Y, Hu B, Liu J, Kong P, Lou S, et al. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation. J Clin Oncol. 2016;34(24):2843\u201350.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4955_CR27","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1089\/scd.2010.0447","volume":"20","author":"K Liu","year":"2011","unstructured":"Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev. 2011;20(10):1679\u201385.","journal-title":"Stem Cells Dev"},{"key":"4955_CR28","doi-asserted-by":"crossref","unstructured":"Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-A phase II study. Stem cells Int. 2012;2012:968213.","DOI":"10.1155\/2012\/968213"},{"issue":"11","key":"4955_CR29","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3727\/096368912X663533","volume":"22","author":"KH Wu","year":"2013","unstructured":"Wu KH, Tsai C, Wu HP, Sieber M, Peng CT, Chao YH. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transpl. 2013;22(11):2041\u201351.","journal-title":"Cell Transpl"},{"issue":"5","key":"4955_CR30","doi-asserted-by":"publisher","first-page":"300060520920438","DOI":"10.1177\/0300060520920438","volume":"48","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang M, He P. Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. J Int Med Res. 2020;48(5):300060520920438.","journal-title":"J Int Med Res"},{"issue":"2","key":"4955_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, et al. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial. JAMA Oncol. 2024;10(2):220\u20136.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4955_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13287-024-04064-w","volume":"15","author":"G Lombardo","year":"2024","unstructured":"Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S, et al. Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review. Stem Cell Res Ther. 2024;15(1):461.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4955_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.leu.2405090","volume":"22","author":"H Ning","year":"2008","unstructured":"Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22(3):593\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"4955_CR34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1134\/S0006297914120104","volume":"79","author":"IN Shipounova","year":"2014","unstructured":"Shipounova IN, Petinati NA, Bigildeev AE, Zezina EA, Drize NI, Kuzmina LA, et al. Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochem (Mosc). 2014;79(12):1363\u201370.","journal-title":"Biochem (Mosc)"},{"issue":"1","key":"4955_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4955_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12916-024-03782-5","volume":"22","author":"E Jiang","year":"2024","unstructured":"Jiang E, Qian K, Wang L, Yang D, Shao Y, Hu L, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Med. 2024;22(1):555.","journal-title":"BMC Med"},{"issue":"5","key":"4955_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","volume":"26","author":"P Kebriaei","year":"2020","unstructured":"Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2020;26(5):835\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"4955_CR38","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.1016\/j.bbmt.2009.12.426","volume":"16","author":"P Szabolcs","year":"2010","unstructured":"Szabolcs P, Visani G, Locatelli F, Kleiner G, Talano J, Nemecek E, et al. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo-controlled study. Biol Blood Marrow Transplant. 2010;16(2):S298.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"28","key":"4955_CR39","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","volume":"33","author":"R Shouval","year":"2015","unstructured":"Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, et al. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol. 2015;33(28):3144\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4955_CR40","doi-asserted-by":"publisher","first-page":"a011825","DOI":"10.1101\/cshperspect.a011825","volume":"2","author":"G Lucarelli","year":"2012","unstructured":"Lucarelli G, Isgr\u00f2 A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2012;2(5):a011825.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"4955_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13287-020-01592-z","volume":"11","author":"C Morata-Tarifa","year":"2020","unstructured":"Morata-Tarifa C, Mac\u00edas-S\u00e1nchez MDM, Guti\u00e9rrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther. 2020;11(1):64.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4955_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13287-021-02304-x","volume":"12","author":"T Li","year":"2021","unstructured":"Li T, Luo C, Zhang J, Wei L, Sun W, Xie Q, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4955_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13287-019-1287-9","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Chen S, Yang P, Cao H, Li L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4955_CR44","first-page":"Cd009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019;1(1):Cd009768.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"4955_CR45","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2010.214","volume":"24","author":"J L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque J, Helwani F, Winkler I. The endosteal \u2018osteoblastic\u2019niche and its role in hematopoietic stem cell homing and mobilization. Leukemia. 2010;24(12):1979\u201392.","journal-title":"Leukemia"},{"issue":"4","key":"4955_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","volume":"13","author":"JF Swart","year":"2017","unstructured":"Swart JF, Delemarre EM, Van Wijk F, Boelens J-J, Kuball J, Van Laar JM, et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017;13(4):244\u201356.","journal-title":"Nat Rev Rheumatol"},{"issue":"7483","key":"4955_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327\u201334.","journal-title":"Nature"},{"issue":"9","key":"4955_CR48","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41409-022-01728-0","volume":"57","author":"F Peci","year":"2022","unstructured":"Peci F, Dekker L, Pagliaro A, van Boxtel R, Nierkens S, Belderbos M. The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2022;57(9):1357\u201364.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4955_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/pharmaceutics14020381","volume":"14","author":"R Alvites","year":"2022","unstructured":"Alvites R, Branquinho M, Sousa AC, Lopes B, Sousa P, Maur\u00edcio AC. Mesenchymal stem\/stromal cells and their paracrine activity\u2014immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics. 2022;14(2):381.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4955_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.15171\/apb.2015.042","volume":"5","author":"M Saleh","year":"2015","unstructured":"Saleh M, Shamsasanjan K, Movassaghpourakbari A, Akbarzadehlaleh P, Molaeipour Z. The Impact of Mesenchymal Stem Cells on Differentiation of Hematopoietic Stem Cells. Adv Pharm Bull. 2015;5(3):299\u2013304.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"4955_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","volume":"7","author":"Y Han","year":"2022","unstructured":"Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022;7(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4955_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.15171\/apb.2017.021","volume":"7","author":"S Aqmasheh","year":"2017","unstructured":"Aqmasheh S, Shamsasanjan K, Akbarzadehlaleh P, Pashoutan Sarvar D, Timari H. Effects of Mesenchymal Stem Cell Derivatives on Hematopoiesis and Hematopoietic Stem Cells. Adv Pharm Bull. 2017;7(2):165\u201377.","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"4955_CR53","first-page":"115","volume":"11","author":"GR Zhu","year":"2003","unstructured":"Zhu GR, Zhou XY, Lu H, Zhou JW, Li AP, Xu W, et al. [Human bone marrow mesenchymal stem cells express multiple hematopoietic growth factors]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11(2):115\u20139.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"4955_CR54","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12015-019-09886-3","volume":"15","author":"A R\u00fchle","year":"2019","unstructured":"R\u00fchle A, Lopez Perez R, Zou B, Grosu A-L, Huber PE, Nicolay NH. The therapeutic potential of mesenchymal stromal cells in the treatment of chemotherapy-induced tissue damage. Stem cell reviews Rep. 2019;15:356\u201373.","journal-title":"Stem cell reviews Rep"},{"key":"4955_CR55","doi-asserted-by":"publisher","first-page":"561098","DOI":"10.1155\/2013\/561098","volume":"2013","author":"LA Marquez-Curtis","year":"2013","unstructured":"Marquez-Curtis LA, Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1\/CXCR4 axis. Biomed Res Int. 2013;2013:561098.","journal-title":"Biomed Res Int"},{"key":"4955_CR56","doi-asserted-by":"crossref","unstructured":"Cagliani J, Grande D, Molmenti EP, Miller EJ, Rilo HLR. Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications. J Stem Cell Regen Biol. 2017;3(2):10-5436.","DOI":"10.15436\/2471-0598.17.022"},{"issue":"6","key":"4955_CR57","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41423-023-01034-9","volume":"20","author":"J Zhou","year":"2023","unstructured":"Zhou J, Shi Y. Mesenchymal stem\/stromal cells (MSCs): origin, immune regulation, and clinical applications. Cell Mol Immunol. 2023;20(6):555\u20137.","journal-title":"Cell Mol Immunol"},{"key":"4955_CR58","doi-asserted-by":"publisher","first-page":"1094685","DOI":"10.3389\/fimmu.2023.1094685","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Wei Q, Lu L, Cui S, Ma K, Zhang W, et al. Immunomodulatory potential of mesenchymal stem cell-derived extracellular vesicles: Targeting immune cells. Front Immunol. 2023;14:1094685.","journal-title":"Front Immunol"},{"key":"4955_CR59","doi-asserted-by":"crossref","unstructured":"Pankajakshan D, Agrawal DK. Mesenchymal Stem Cell Paracrine Factors in Vascular Repair and Regeneration. J Biomed Technol Res. 2014;1(1):10-9104.","DOI":"10.19104\/jbtr.2014.107"},{"issue":"9","key":"4955_CR60","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","volume":"41","author":"N Song","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020;41(9):653\u201364.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4955_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13287-018-0791-7","volume":"9","author":"S Keshtkar","year":"2018","unstructured":"Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018;9(1):63.","journal-title":"Stem Cell Res Ther"},{"key":"4955_CR62","doi-asserted-by":"crossref","unstructured":"Xiao-Ni L, Zhang C-B, Hai L, Xiao-Yuan T, Rong Z, Hui-Lan W et al. microRNA-204 shuttled by mesenchymal stem cell-derived exosomes inhibits the migration and invasion of non-small-cell lung cancer cells via the KLF7\/AKT\/HIF-1\u03b1 axis. Neoplasma. 2021;68:4.","DOI":"10.4149\/neo_2021_201208N1328"},{"issue":"5","key":"4955_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.it.2007.03.001","volume":"28","author":"A Uccelli","year":"2007","unstructured":"Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28(5):219\u201326.","journal-title":"Trends Immunol"},{"issue":"9","key":"4955_CR64","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4252\/wjsc.v8.i9.268","volume":"8","author":"OK Ma","year":"2016","unstructured":"Ma OK, Chan KH. Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes. World J Stem Cells. 2016;8(9):268\u201378.","journal-title":"World J Stem Cells"},{"issue":"17","key":"4955_CR65","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1007\/s00018-016-2229-7","volume":"73","author":"M Mo","year":"2016","unstructured":"Mo M, Wang S, Zhou Y, Li H, Wu Y. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cell Mol Life Sci. 2016;73(17):3311\u201321.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"4955_CR66","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1002\/hsr2.282","volume":"4","author":"M Rafiee","year":"2021","unstructured":"Rafiee M, Abbasi M, Rafieemehr H, Mirzaeian A, Barzegar M, Amiri V, et al. A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes. Health Sci Rep. 2021;4(2):e282.","journal-title":"Health Sci Rep"},{"key":"4955_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers15194758","volume":"15","author":"LS Zubarovskaya","year":"2023","unstructured":"Zubarovskaya LS, Moiseev IS, Vladovskaya MD, Mikhailova NB, Morozova EV, Bykova TA, et al. Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience. Cancers (Basel). 2023;15:19.","journal-title":"Cancers (Basel)"},{"key":"4955_CR68","first-page":"204993612110056","volume":"8","author":"KK Sahu","year":"2021","unstructured":"Sahu KK. Infectious disease in hematopoietic stem cell transplantation. Ther Adv Infect Dis. 2021;8:20499361211005600.","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"4955_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/ijc.IJC_656_17","volume":"55","author":"N Khattry","year":"2018","unstructured":"Khattry N, Laskar S, Sengar M, Rangarajan V, Shet T, Subramanian PG, et al. Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian J Cancer. 2018;55(1):9\u201315.","journal-title":"Indian J Cancer"},{"issue":"13","key":"4955_CR70","first-page":"2042","volume":"28","author":"W Zhang","year":"2024","unstructured":"Zhang W, Pei X, Kong D, Liu Z. Efficacy of umbilical cord mesenchymal stem cells replacing donor bone marrow cells in haploidentical hematopoietic stem cell transplantation. Chin J Tissue Eng Res. 2024;28(13):2042.","journal-title":"Chin J Tissue Eng Res"},{"issue":"12","key":"4955_CR71","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2023020073","volume":"142","author":"O Jamy","year":"2023","unstructured":"Jamy O, Zeiser R, Chen YB. Novel developments in the prophylaxis and treatment of acute GVHD. Blood. 2023;142(12):1037\u201346.","journal-title":"Blood"},{"issue":"1","key":"4955_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/bmt.2016.225","volume":"52","author":"I Garc\u00eda-Cadenas","year":"2017","unstructured":"Garc\u00eda-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplant. 2017;52(1):107\u201313.","journal-title":"Bone Marrow Transplant"},{"key":"4955_CR73","doi-asserted-by":"publisher","first-page":"632717","DOI":"10.3389\/fcell.2021.632717","volume":"9","author":"A Wright","year":"2021","unstructured":"Wright A, Arthaud-Day ML, Weiss ML. Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species. Front cell Dev biology. 2021;9:632717.","journal-title":"Front cell Dev biology"},{"issue":"6","key":"4955_CR74","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018;22(6):824\u201333.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"4955_CR75","doi-asserted-by":"publisher","first-page":"e12472","DOI":"10.1002\/jev2.12472","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Sun L, Li Y, Holmes C. Mesenchymal stromal\/stem cell tissue source and in vitro expansion impact extracellular vesicle protein and miRNA compositions as well as angiogenic and immunomodulatory capacities. J Extracell Vesicles. 2024;13(8):e12472.","journal-title":"J Extracell Vesicles"},{"key":"4955_CR76","doi-asserted-by":"publisher","first-page":"1400347","DOI":"10.3389\/fcell.2024.1400347","volume":"12","author":"AB \u010cesnik","year":"2024","unstructured":"\u010cesnik AB, \u0160vajger U. The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review. Front Cell Dev Biol. 2024;12:1400347.","journal-title":"Front Cell Dev Biol"},{"key":"4955_CR77","first-page":"100018","volume":"2","author":"C Sanz-Nogu\u00e9s","year":"2021","unstructured":"Sanz-Nogu\u00e9s C, O\u2019Brien T. Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents. Biomater Biosyst. 2021;2:100018.","journal-title":"Biomater Biosyst"},{"key":"4955_CR78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21037\/sci.2019.08.11","volume":"6","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig. 2019;6:34.","journal-title":"Stem Cell Investig"},{"issue":"1","key":"4955_CR79","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41467-019-14000-9","volume":"11","author":"AY Clark","year":"2020","unstructured":"Clark AY, Martin KE, Garc\u00eda JR, Johnson CT, Theriault HS, Han WM, et al. Integrin-specific hydrogels modulate transplanted human bone marrow-derived mesenchymal stem cell survival, engraftment, and reparative activities. Nat Commun. 2020;11(1):114.","journal-title":"Nat Commun"},{"key":"4955_CR80","doi-asserted-by":"publisher","first-page":"119403","DOI":"10.1016\/j.biomaterials.2019.119403","volume":"220","author":"JR Garc\u00eda","year":"2019","unstructured":"Garc\u00eda JR, Quir\u00f3s M, Han WM, O\u2019Leary MN, Cox GN, Nusrat A, et al. IFN-\u03b3-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials. 2019;220:119403.","journal-title":"Biomaterials"},{"issue":"7","key":"4955_CR81","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3324\/haematol.10669","volume":"92","author":"M Shi","year":"2007","unstructured":"Shi M, Li J, Liao L, Chen B, Li B, Chen L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD\/SCID mice. Haematologica. 2007;92(7):897\u2013904.","journal-title":"Haematologica"},{"issue":"1","key":"4955_CR82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13287-017-0692-1","volume":"8","author":"Y Gothelf","year":"2017","unstructured":"Gothelf Y, Kaspi H, Abramov N, Aricha R. miRNA profiling of NurOwn\u00ae: mesenchymal stem cells secreting neurotrophic factors. Stem Cell Res Ther. 2017;8(1):249.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"4955_CR83","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147\u201359.","journal-title":"Lancet Haematol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04955-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:01:47Z","timestamp":1776081707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04955-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4955"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04955-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}